Entity

Time filter

Source Type

Ridgefield, CT, United States

C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 140 affiliates and more than 47,000 employees. The company's key assets of interest are: respiratory diseases, cardiovascular diseases, Parkinson's disease, HIV, thromboembolic diseases, cerebrovascular diseases, oncology, diabetes and hepatitis. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.In October 2012 Boehringer Ingelheim settled a "qui tam" case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On May 28, 2014,a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug. Wikipedia.


Xu G.,CAS Shanghai Institute of Organic Chemistry | Fu W.,CAS Shanghai Institute of Organic Chemistry | Liu G.,CAS Shanghai Institute of Organic Chemistry | Senanayake C.H.,Boehringer Ingelheim Pharmaceuticals | Tang W.,CAS Shanghai Institute of Organic Chemistry
Journal of the American Chemical Society | Year: 2014

Efficient asymmetric Suzuki-Miyaura coupling reactions are employed for the first time in total syntheses of chiral biaryl natural products korupensamine A and B in combination with an effective diastereoselective hydrogenation, allowing ultimately a concise and stereoselective synthesis of michellamine B. Chiral monophosphorus ligands L1-3 are effective for the syntheses of a series of functionalized chiral biaryls by asymmetric Suzuki-Miyaura coupling reactions in excellent yields and enantioselectivities (up to 99% ee). The presence of a polar-π interaction between the highly polarized BOP group and the extended π system of arylboronic acid coupling partner is believed to be important for the high enantioselectivity. © 2013 American Chemical Society. Source


Michel M.C.,Boehringer Ingelheim | Michel M.C.,Johannes Gutenberg University Mainz | Foster C.,Boehringer Ingelheim Pharmaceuticals | Brunner H.R.,University of Lausanne | Liu L.,Beijing Hypertension League Institute
Pharmacological Reviews | Year: 2013

Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some ismediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-g. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed. © 2013 by The American Society for Pharmacology and Experimental Therapeutics. Source


Patent
Boehringer Ingelheim Pharmaceuticals | Date: 2010-08-13

An automated data processing method for obtaining clinical data for safety, efficacy, and adverse event assessments pertaining to a therapy prescribed for the treatment of a malady, comprising the step of receiving at a location remote from a plurality of patients outcome digital information pertaining to the outcome of therapies performed on said patients, and for the efficient delivery of medications to a patient ordered pursuant to an electronic prescription from a dispensary optimized for delivery of the medication.


Patent
Boehringer Ingelheim Pharmaceuticals | Date: 2011-12-19

A method for modulating NF-B dependent gene transcription in a cell comprised of modulating IKK and IKK protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-B dependent gene transcription.


Patent
Boehringer Ingelheim Pharmaceuticals | Date: 2011-07-27

An automated data processing method for obtaining clinical data for safety, efficacy, and adverse event assessments pertaining to a therapy prescribed for the treatment of a malady, comprising the step of receiving at a location remote from a plurality of patients outcome digital information pertaining to the outcome of therapies performed on said patients, and for the efficient delivery of medications to a patient ordered pursuant to an electronic prescription from a dispensary optimized for delivery of the medication.

Discover hidden collaborations